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SUMMARY 2 
Nutritional psychiatry is a growing area of research, with several nutritional factors implicated in the 3 
aetiology of psychiatric ill health. However, nutritional research is highly complex, with multiple 4 
potential factors involved, highly confounded exposures and small individual effect sizes. This paper 5 
considers whether Mendelian randomization provides a solution to these difficulties, by 6 
investigating causality in a low risk and low-cost way. Current studies using MR in nutritional 7 
psychiatry are reviewed, along with the potential opportunities and challenges of using this 8 
approach for investigating the causal effects of nutritional exposures. Several studies have identified 9 
potentially causal nutritional exposures using Mendelian randomisation in psychiatry, offering 10 
opportunities for further mechanistic research, intervention development, and replication. Using 11 
Mendelian randomisation as a foundation for intervention development allows the best use of 12 
resources in an emerging discipline in which opportunities are rich, but resources are often poor.  13 
 14 
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INTRODUCTION  28 
The founding of the International Society for Nutritional Psychiatry Research1 reflects an 29 
increasing recognition of nutrition as a modifiable risk factor for mental ill-health, and the need for 30 
good quality research in this area. Whilst the adverse psychological effects of severe nutritional 31 
deficiency are well established,2 the extent to which subtle nutritional factors might have on 32 
cognitive and affective processes, or on the increasing burden of psychological ill health at the 33 
population level remains unclear.  As wholefood diets have been replaced by processed foods - high 34 
in sugar and low in essential fats, vitamins and minerals - many argue that subtle malnutrition may 35 
exist even in the presence of calorie-abundance,3, 4 with unclear repercussions for population mental 36 
health.  Several meta-analyses of prospective studies suggest that a high-quality diet can reduce the 37 
risk of mental illness,5, 6 warranting further investigation of specific nutritional factors and 38 
mechanisms.Conventional epidemiological associations between nutritional intake or status and 39 
psychiatric outcomes are highly prone to confounding by lifestyle and correlated dietary factors.7 40 
Furthermore, as many aspects of nutrition are affected by mental ill-health,8 it is likely that reverse 41 
causality, or at least a bi-directional relationship, explains some of these associations. Finally, as 42 
individual nutrients have small effect sizes, large sample sizes are required to explore such 43 
associations with adequate statistical power, in which accurate dietary measurement is difficult. 44 
Despite the best efforts of researchers to control for these limitations, nutritional epidemiology is 45 
limited by issues of residual confounding, biological complexities and limited power.  46 
Interventional research in nutritional psychiatry is a potential solution to these limitations, 47 
as good quality randomized controlled trials (RCTs) eliminate issues of confounding and reverse 48 
causality.  There are a growing number of RCTs in nutritional psychiatry. Although many studies have 49 
focused on individual nutritional supplements - probably reflecting the parallels with a 50 
pharmacological research model ,9-11 there are few supplements that have been robustly identified 51 
as beneficial in psychiatry.11 Results are often inconsistent, and it is unclear which interventions are 52 
worth further investment. Given the complexities and inter-relatedness of dietary composition, a 53 
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more comprehensive nutritional approach may be preferable. Combination micronutrient 54 
supplement interventions12-14 and interventions focused on making broader changes to dietary 55 
patterns might be advantageous.15, 16 Dietary pattern interventions offer a potential solution to this 56 
complexity, with supporting meta-analytical evidence in both observational5 and interventional 57 
research17. However, selecting the right intervention and participants, and accounting for behaviour 58 
change and attrition, make the planning and evaluation of such trials complex and costly. With a 59 
multitude of potential nutritional interventions, it can be difficult to prioritise the most likely to be 60 
effective. False negatives from underpowered designs or minor aberrations in a complex 61 
intervention, might hinder the development of potentially beneficial interventions. Conversely, false 62 
positives due to biased designs, compounded by publication bias, lead to wasted expenditure and 63 
potential harm in repeated trials. Further evidence to establish likely causality for specific nutritional 64 
factors to underpin nutritional interventions and identify the most likely beneficial components 65 
would prevent wasted time and expenditure. 66 
This paper considers whether ‘Mendelian randomization’ is a viable method to inform 67 
intervention development in nutritional psychiatry, in a low-cost and low-risk way. We review 68 
existing Mendelian randomization studies in nutritional psychiatry, the challenges faced, and 69 
opportunities for further research.  70 
 71 
MENDELIAN RANDOMIZATION 72 
Mendelian randomization (MR) is a method that is increasingly used to infer causality in 73 
epidemiological research. MR uses genetic markers that are robustly associated with a particular 74 
potentially modifiable exposure as ‘instrumental variables’ in assessing the relationship between an 75 
exposure and an outcome.18, 19As genetic markers (or ‘alleles’) are randomly allocated at conception, 76 
many have compared MR to a natural RCT, in which variant alleles rather than  77 
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Interventions are randomized (figure 1a). The individual variations in genetic alleles are referred to 78 
as single nucleotide polymorphisms (SNPs). MR exploits this natural genetic variation to circumvent 79 
the problem of confounding and reverse causality (figure 1a).  80 
The concept of MR relies on key assumptions for validity (figure 1b). Whilst a comprehensive 81 
review of MR is beyond the scope of this review, some key terms used to describe aspects of MR 82 
studies relevant to this review are explained in Table 1. For more detail, see Zheng et al 201720 and 83 
the MR Dictionary.21 84 
There are potential benefits to applying MR methodology to nutritional psychiatry, as a 85 
cheap and powerful method for attributing causality to putative exposures, and it enables the 86 
exploration of multiple avenues for intervention development in a low-cost and low-risk way. This is 87 
particularly true with the development of two-sample MR, in which exposures and outcomes need 88 
not be measured in the same sample (figure 1c). Two-sample MRtakes estimates of the SNP-89 
exposure association from a one population (for example a genome-wide association study (GWAS) 90 
of a nutritional exposure,) and the SNP-outcome association from another (for example a GWAS of a 91 
given psychiatric outcome). This allows for the possibility of utilising the increasing sample sizes 92 
provided by large psychiatric genetic consortia, without the need to access individual-level data on 93 
specific nutritional measures. Given the relatively small effect sizes, and modest genetic contribution 94 
to nutritional exposures, a two-sample MR methodology using large outcome samples should 95 
provide adequate power to investigate them. 96 
One  advantage of MR is that, providing appropriate genetic instruments are available, it is 97 
theoretically possible to model the results of certain randomised trials, thereby reducing 98 
unnecessary potential harms and expenditure. One example in the context of nutritional 99 
epidemiology was given by a recent MR study to model the Selenium and Vitamin E Cancer 100 
Prevention Trial (SELECT) for prostate cancer, which was based on extensive epidemiological 101 
evidence at that time. The SELECT trial, randomised 35,533 men to use selenium supplementation, 102 
to investigate whether increasing selenium levels might prevent prostate cancer.22 The $114 million 103 
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trial ended prematurely as results showed that selenium supplementation not only failed to reduce 104 
prostate cancer risk, it was likely to increase the risk of advanced prostate cancer and type 2 105 
diabetes mellitus. These results were replicated by MR, using genetic instruments for circulating 106 
selenium in the PRACTICAL consortium.23 Although retrospective, the MR study took a fraction of the 107 
financial and time burden of a trial, and more importantly avoided any potential harm to 108 
participants.23 109 
A comparison between MR and a naturalised RCT, has its limitations. Firstly, as genetic 110 
variants reflect lifetime exposures rather than short durations of therapeutic intervention, MR may 111 
produce a stronger effect than in the best approximation of a time-limited intervention. Conversely, 112 
individual adaptation to genotype may reduce the effect of the SNP on the exposure and so may 113 
underestimate the effect (also known as canalization (see table 1)). Rather than a replacement for 114 
RCTs, MR might be viewed as a foundation from which interventions for further development can be 115 
identified, in combination with epidemiology and basic science, also referred to as triangulation24 116 
(figure 2).   117 
MR may be particularly useful for a field such as nutritional psychiatry, in which many of the 118 
interventional trials have small to modest sample sizes. A well-powered MR study can be used to 119 
verify results in a potentially underpowered study, as well as to inform future studies. MR studies 120 
showing no evidence for a causal effect need careful consideration about whether it is possible to 121 
rule out a clinically significant effect based on the available parameters, and whether replication 122 
using updated background literature would be beneficial at a future date. This includes whether the 123 
methods and instruments are valid, power is adequate, and whether biological complexity might 124 
complicate results. This is particularly relevant in psychiatry, where diagnostic categorisation is yet 125 
to account for the diversity of symptoms and presentations categorized by a single ‘disorder’. 126 
Studies showing strong evidence for an effect need equal consideration before intervention 127 
development is considered, - such as how to increase the nutritional exposure in the desired way, 128 
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whether participants are selected based on deficiency states, and whether supplementation might 129 
have potential adverse effects. 130 
 131 
MENDELIAN RANDOMIZATION STUDIES IN NUTRITIONAL PSYCHIATRY 132 
We identified 26 studies using MR to investigate causality in nutritional psychiatry (Table 2). 133 
Many have investigated a single exposure or outcome, but some have investigated multiple 134 
exposures and outcomes within the same paper. The studies are broadly grouped into three main 135 
psychiatric outcomes - cognitive impairment and dementia, schizophrenia, and mood disorders. 136 
 137 
Dementia and Cognition 138 
We identified 17 studies using MR to investigate the causality of nutritional factors on 139 
dementia and cognitive outcomes. Evidence suggesting a protective effect of 25-hydroxyvitamin D 140 
(25(OH)D) in Alzheimer’s disease has been shown in two studies in the International Genomics of 141 
Alzheimer’s Project (IGAP) Cohort (OR 0·86 per SD increase in vitamin D, 95% CI 0·78 to 0·94),25, 26 142 
but not replicated in the Uppsala Longitudinal Study (Hazard ratio per allele 1.04, 95% CI 0.91 to 143 
1.19).27 Studies investigating 25(OH)D as a causal factor in cognitive function have found no evidence 144 
for an association.27-29 It may be that vitamin D is particularly relevant to Alzheimer’s pathology, or 145 
that larger sample size or stronger genetic instruments are required to identify the effects in non-146 
clinical population samples. Furthermore, a possible non-linear observational association between 147 
vitamin D and cognition, with both deficiency and excess associated with poor cognition, was noted 148 
by Maddock et al 2017.29 This raises important considerations about the ability of traditional MR 149 
techniques to detect causality for cognitive outcomes,29 as well as other associations in which a 150 
similar relationship has been noted.30 Novel methods are being developed to manage non-linearity 151 
in MR,31 but are not commonly employed.  152 
Studies investigating the causal role for B vitamin pathways in dementia have had mixed 153 
results. A study looking at multiple exposures using the IGAP cohort did not provide evidence for 154 
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folate (OR 0·98 per SD, 95% CI 0·72 to 1·33), homocysteine (OR 0·99 per SD, 95% CI 0·88 to 1·11) or 155 
vitamin B12 (OR 1·11 per SD, 95% CI 0·95 to 1·30) in Alzheimer’s disease.32 However, previous 156 
studies looking at homocysteine using a single SNP in the methylenetetrahydrofolate reductase 157 
(MTHFR) gene have suggested strong evidence of causality.33 The MTHFR gene produces an enzyme 158 
which activates folate to metabolise homocysteine, and SNPs in this gene have been identified in 159 
GWAS of both homocysteine and circulating folate levels. However, some have suggested caution in 160 
the use of the MTHFR gene for MR due to a complex interaction with folate intake, in which the 161 
same polymorphism leading to reduced enzymatic activity in low-intake states (and therefore low 162 
blood folate and high homocysteine), may not have any effect on blood folate or high homocysteine 163 
in high-intake states.34 Several MR studies of homocysteine using a single SNP relating to MTHFR 164 
have failed to replicate using instruments containing more SNPs and explaining a greater variation in 165 
homocysteine levels, suggesting that this SNP may be acting via a different mechanistic pathway. A 166 
meta-analysis of the results for homocysteine in Alzheimer’s disease using the different instruments 167 
suggests some causal evidence for homocysteine (pooled effect 1.34 per SD, 95% CI 1.03 to 1.66), 168 
but in light of the complex biology, this may be misleading. Another study investigating vascular 169 
dementia using the same single SNP in the MTHFR gene also showed strong causal evidence for  170 
homocysteine (OR 4·29 per SD log(homocysteine), 95% CI 1·11 to 16·57).35 However, the same 171 
caveats apply. 172 
A single identified study has investigated amino acids in psychiatric disease, suggesting a 173 
potential causal role for isoleucine in Alzheimer’s disease (OR 1·35 per SD, 95% CI 1.08 to 1.69), 174 
though not for other branched chain amino acids such as valine and leucine.36  175 
The established link between APOE genotype and Alzheimer’s has been corroborated using 176 
MR studies (OR 1.41 per mg/dL of APOE, 95% CI 1.27 to 1.57).37 Further exploration of the role of 177 
lipids in dementia have not shown evidence for a causal role for any specific lipid faction when the 178 
APOE SNPs are excluded from analysis.38, 39 MR studies investigating fasting glucose (OR 1·12 per SD, 179 
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95% CI 0·97 to 1·30),40 and vitamin E levels (OR 0·96 per SD, 95% CI 0·47 to 1·94),41 have not found 180 
any evidence for a causal association. A single study investigating minerals using several psychiatric 181 
outcomes including Alzheimer’s disease found no causal evidence for magnesium (0.43 per SD, 95% 182 
CI 0.08 to 2.44), calcium (Ca 0·74 per SD, 95% CI 0·45 to 1·22), Iron (1·02 per SD, 95% CI 0·94 to 1·14) 183 
or zinc (0·99 per SD, 95% CI 0·85 to 1·14), with weak evidence for low copper (0·87 per SD, 95% CI 184 
0·75 to 1·00).42 185 
 186 
Schizophrenia 187 
We identified six studies that have investigated nutritional exposures in schizophrenia using 188 
MR. There was weak causal evidence for vitamin B6 (OR 0·99 per SD log(B6), 95% CI 0·65 to 1·51),43 189 
and for serum minerals (Calcium, Serum Magnesium, Copper, Iron and Zinc, see Table 2) in 190 
schizophrenia.42 Two studies have identified an association between homocysteine and 191 
schizophrenia, in European (2·15 per SD, 95% CI 1·39 to 3·32)44 and Japanese populations (1.14 per 192 
SD, 95% CI 1.03 to 1.27);45 however, both used a single SNP related to the MTHFR gene, with the 193 
aforementioned limitations. A study looking at the causal role of glucose and insulin related traits 194 
found some evidence for fasting glucose (OR 0·84 per SD, 95% CI 0·71 to 0·99), but strong evidence 195 
for fasting insulin levels (OR 2·33 per SD, 95% CI 1·40 to 3·90).46 Given the discrepancy with the 196 
strength of effect of fasting glucose in the same study, it is likely that insulin partially acts through an 197 
independent pathway to glucose, possibly related to a direct action as a ‘neuropeptide’, involved in 198 
neuroplasticity and modulation. 199 
In contrast to findings in multiple sclerosis47 and Alzheimer’s Disease,26, 27 no strong causal 200 
evidence has been found for vitamin D in schizophrenia (OR 0·99 per 10% increase in 25(OH)D, 95% 201 
CI 0·97 to 1·01).48 This may suggest that the observational estimate is the result of confounding or 202 
reverse causality, but it is also possible that standard MR techniques have been unable to detect a 203 
true causal association due to limited power, population stratification, or biological complexities 204 
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(table 4). Although the power of the study appears more than adequate (example sample sizes 205 
based on MR power calculations are shown in table 3), diagnosis of schizophrenia is comparatively 206 
vague, and more subject to symptom interpretation that for an outcome such as multiple sclerosis 207 
or Alzheimer’s Disease. This heterogeneity may require larger sample sizes to identify causal effects 208 
of a similar magnitude. A second limitation is MR results represent the causal impact of a lifetime 209 
exposure on an outcome, it is unable to account for exposures that are time-limited or during a 210 
sensitive period.  211 
For example, if the sensitive period for vitamin D deficiency is intrauterine, as suggested by 212 
the higher prevalence among winter-born individuals,49 an MR analysis would not reflect this. Finally, 213 
standard MR techniques assume a linear relationship between exposure and outcome, which in the 214 
case of vitamin D might be a fallacy, as both deficiency and excess states may be harmful.30 Standard 215 
MR techniques assume a linear association between the exposure and outcome, and whilst novel 216 
methods are being developed to overcome this limitation, they are not yet standard practice.31  217 
 218 
Mood Disorders 219 
Several nutritional factors have been investigated using MR in major depression samples, 220 
with no strong evidence of effect. Nutritional factors include vitamins  B12 and folate,50 omega 3 221 
fatty acids,51 and 25-hydroxyvitamin D.52 The five minerals investigated in Cheng 2019 did not show 222 
evidence of causality, though the Psychiatric Genomics Consortium sample used as the outcome is 223 
small (N=10,640) in comparison to the latest PGC Major Depression sample (N=807,553).42 An MR 224 
study using the Young Finns study 53 showed an inverse association between fasting glucose and 225 
depressive symptoms measured using the Beck Depression Inventory, (−0·43 BDI points per 226 
weighted effect allele, 95% CI −0·79 to 0·07), which the authors hypothesise to relate to the 227 
cognitive effects of hypoglycaemia. A study in UK Biobank suggested a potentially causal role for 228 
elevated triglycerides (but not LDL- or HDL-cholesterol) in the development of lifetime major 229 
depression (OR 1.18 per SD (1·09–1·27)).54  230 
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An MR study looking at multiple minerals identified a potentially causal role for low copper 231 
(OR 0·87 per SD, 95% CI 0·79 to 0·97) and for high serum magnesium (OR 8·78 per SD, 95% CI 1·16 to 232 
66·26) in bipolar disorder using the Bipolar Disorder Working Group sample of the Psychiatric 233 
Genomics Consortium. Both findings warrant replication and further investigation. Some 234 
observational literature has suggested higher serum magnesium (though lower intracellular 235 
magnesium) levels in bipolar disorder, and the pathophysiological mechanisms behind this could be 236 
further explored using two-step MR (figure 3a). 237 
 238 
OPPORTUNITIES FOR MR IN NUTRITIONAL PSYCHIATRY 239 
Although one of the biggest challenges for MR in nutritional psychiatry to date has been the 240 
lack of appropriate genetic instruments, nutritional genetics is evolving. Instruments for many 241 
nutritional exposures are being utilised in MR studies outside psychiatry or applied to only one of a 242 
multitude of psychiatric outcomes. In addition to biological nutritional markers, GWAS of dietary 243 
intake,55 dietary patterns,56 and even gut microbial diversity,57 may provide useful potential 244 
instruments for future MR studies aiming to assess the impact of nutritional  characteristics on 245 
psychiatric ill-health. For example, evidence suggests that gut microbial diversity and abundance is 246 
influenced by human genetics,57 making MR studies of this exposure possible, with examples of 247 
causal relationships being identified using MR in other areas of medicine.58 MR studies of the gut 248 
microbiome characterised in different ways may help to explain the association between reduced 249 
gut microbiome diversity and the presence of specific bacterial taxa in psychiatric disease,59 and the 250 
apparent benefits of probiotics in psychiatry.60, 61  251 
MR methods are continually evolving (see table 1), with several techniques relevant to 252 
research in nutritional psychiatry. An example is multivariable MR (see figure 3b), which can be 253 
employed in situations where genetic variants are related to several correlated exposures. 254 
Multivariable MR has been used successfully in untangling the association between high density 255 
lipoprotein cholesterol, low density lipoprotein cholesterol, and triglycerides with cardiovascular 256 
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disease62 and depression.54 Multivariable MR could similarly be used to unpick potentially complex 257 
associations, such as between omega 3 and 6 fatty acids, or B vitamin pathways, in psychiatry. For 258 
positive findings in nutritional psychiatry, potential off-target adverse effects of nutritional 259 
supplementation could be identified using MR phenome-wide association study (MR-PheWAS).63 An 260 
MR-PheWAS uses a hypothesis-free approach to scan many outcomes for a given exposure, and 261 
could have potentially pre-empted the increased risk of diabetes with selenium supplementation 262 
seen in the SELECT trial.23 As well as informing intervention development, MR can also be used to 263 
investigate biological mechanisms in psychiatry including metabolomic, microbiomic, proteomic and 264 
epigenomic intermediates, using two-step MR.64 Two-step MR is a relatively new method for 265 
identifying and quantifying mediating mechanisms between an exposure and outcome using an MR 266 
framework (figure 3a). Novel MR methods to analyse gene-environment interactions are also under 267 
development, and may be particularly useful in the context of nutritional psychiatry. Finally, using 268 
MR of the human proteome in relation to psychiatric outcomes may identify novel drug targets.  269 
Standard MR methods rely on a single exposure-outcome framework, which many consider 270 
to be oversimplified when in the context of complex nutritional biology. Many nutritional 271 
epidemiologists have moved beyond a single nutrient approach to consider whole dietary patterns, 272 
adiposity, and the inherently complex interaction between diet, hormones and physical activity.65 It 273 
is possible that future MR methods could consider interactions between other nutritional exposures, 274 
as well as with gene-environment interactions considering nutritional intake or other lifestyle 275 
factors. Techniques such as machine learning and data mining using nutritional exposures, genetic 276 
data, dietary intake and psychiatric diagnoses and symptoms might be necessary for unpicking 277 
complex associations and gene-environment interactions further. Machine learning has already been 278 
suggested for augmenting MR, by predicting the most appropriate model to optimise power and 279 
detect pleiotropy, and could potentially enhance MR in the complex arena of nutritional 280 
psychiatry.66 281 
 282 
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CHALLENGES FOR MR IN NUTRITIONAL PSYCHIATRY 283 
With increasing availability of genetic instruments, genetic samples, and platforms for MR 284 
analysis, false results can be obtained quickly. Results need careful consideration as to validity of the 285 
methods, samples, and instruments used, irrespective of their strength or direction. Subsequent 286 
replication in independent cohorts remains crucial.19  287 
Several limitations of traditional MR methods may hinder the application to nutritional 288 
psychiatry (see table 4). The lack of valid, robust genetic instruments for many nutritional exposures 289 
is arguably one of the most fundamental limitations. GWAS studies identifying SNPs robustly 290 
associated with nutritional exposures depend on adequately sized genotyped samples of nutritional 291 
factors. Difficulties identifying robust and reliable nutritional biomarkers reflecting nutritional status 292 
may underlie this, along with the availability of such nutritional measures in adequately sized 293 
genotyped cohorts. Instruments that are only weakly associated with the exposure of interest (e.g. 294 
F-statistic <10, see table 2) will bias estimates in different directions depending on whether a one-295 
sample or two-sample methodology is used (table 4). 296 
Nutritional genetic epidemiology is a developing field and the expectation is that good 297 
quality, validated instruments for nutritional exposures should emerge and evolve. However, even 298 
where genetic instruments appear to exist, some consideration needs to be given to whether they 299 
are valid for the specific association being tested with MR analyses, checking as far as possible that 300 
the assumptions of MR hold, and by understanding their underlying biological function. 301 
With the increasing development of large psychiatric genomics consortia samples, outcome 302 
sample sizes are rapidly increasing. At first glance these appear to provide ample power to detect 303 
nutritional exposures, even those with a very small effect (see table 3.)19 However, as sample sizes 304 
increase, it is important to consider the extent to which the genetic heterogeneity of the population 305 
has increased, and the validity of the genetic instrument within this new population structure. 306 
Furthermore, the risk of overlapping exposure and outcome samples may invalidate some of the 307 
assumptions of two-sample MR. The relative benefits of using small samples with precisely 308 
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measured nutritional exposures and psychiatric symptomatology, compared to large samples with 309 
imprecise measures and heterogenous samples are not always clearly defined. 310 
 311 
FUTURE DIRECTIONS 312 
Genetic epidemiology is evolving. Sample sizes, genetic markers and MR techniques are 313 
continuing to increase in both number and complexity. Negative early findings need careful 314 
consideration, and positive findings warrant replication in independent cohorts. As sample sizes and 315 
genetic instruments develop, formal repetition of earlier studies and independent replication 316 
remains essential. Given the relative ease with which analyses can be conducted once an instrument 317 
is identified, a more systematic and thorough approach to evaluating nutritional factors in psychiatry 318 
would be beneficial, perhaps considering individual psychiatric presentations along with a ‘cross-319 
disorder’ approach. Opportunities for undertaking GWAS of nutritional biomarkers should be sought 320 
and validated, to make future MR studies possible. Future MR studies should consider novel MR 321 
techniques such as multivariable MR where appropriate, techniques for accounting for non-linear 322 
associations, as well as two-step MR to identify causal mechanisms. Further understanding of gene-323 
environment interactions using large biobanks with data on genetics as well as nutritional and 324 
lifestyle measures might be useful for triangulating with nutritional MR studies. Finally, as the 325 
research landscape evolves, replication of earlier studies using larger samples and improved genetic 326 
instruments, continues to be of value.  327 
Beyond genetics, ongoing research from a broad range of disciplines including epidemiology, 328 
basic sciences, and clinical trials is needed, to identify novel biomarkers of nutritional intake and 329 
status, to develop new technologies for accurate dietary assessment, and to apply the results of MR 330 
studies to inform and conduct large-scale pragmatic trials. 331 
 332 
CONCLUSION 333 
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Nutritional psychiatry, nutritional genetic epidemiology and psychiatric genetics are all at 334 
relatively early stages in their understanding. MR in nutritional psychiatry sits at the centre of these 335 
emerging disciplines, providing a unique way to investigate causality in nutritional psychiatry and 336 
understand its mechanisms. Despite some challenges in this area, emerging MR evidence for 337 
nutritional factors including vitamin D, folate, serum magnesium, copper, triglycerides, and glucose 338 
metabolic pathways on psychiatric outcomes highlight the potential utility of this technique for 339 
identifying causal factors in nutritional psychiatry and developing a firm evidence base for the 340 
causality of nutritional exposures from which successful interventions can develop. 341 
 342 
SEARCH STRATEGY AND SELECTION CRITERIA  343 
References for this review were identified through systematic searches of OVID Medline 344 
(1946 to January 2019,) PsycINFO (1808 to January 2019) and EMBASE (1974-2019) database for 345 
articles published from by use of the terms “Mendelian randomization”, “Psychiatry OR Psychology”, 346 
and other diagnostic terms (see Appendix 1). All abstracts identified were screened to include any 347 
exposure related to nutrition. Exposures were included if they measured any factor that was directly 348 
related to nutritional components or nutritional status, including micronutrients (including vitamins 349 
and minerals), macronutrients (including glucose homeostatic markers, amino acids and peptides 350 
and lipids), and biological markers of nutritional status. These factors were not selected a priori, but 351 
identified post-hoc based on the MR exposures available. Studies using psychiatric diagnosis as an 352 
exposure rather than outcome, addressing broader lifestyle exposures such as body mass index, 353 
physical activity or alcohol, and considered inter-generational exposures (such as offspring outcomes 354 
of pregnancy exposures) were excluded. A full search strategy is given in Appendix 1, with a 355 
flowchart of included studies in Appendix 2. No exclusions were made on the basis of language. 356 
  357 
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RESEARCH IN CONTEXT 358 
Evidence before this study 359 
Nutritional psychiatry is an emerging area of research, but its complexities are numerous. Several 360 
nutritional factors have been implicated in psychiatric aetiology, but causal evidence remains scarce. 361 
Mendelian randomization (MR) is an epidemiological method that can help investigate causality. 362 
Outside of psychiatry, MR has identified likely causal associations between low vitamin D and 363 
multiple sclerosis, low serum iron and Parkinson’s disease, and low serum magnesium and 364 
cardiovascular disease. We searched the OVID Medline database for studies using “Mendelian 365 
randomization” with any outcome related to “Psychiatry OR Psychology”. We excluded studies in 366 
which psychiatric conditions were used as an exposure rather than outcome, which used broader 367 
lifestyle exposures such as body mass index, physical activity or alcohol, and for which the exposure 368 
and outcome was inter-generational (such as offspring outcomes of pregnancy exposures).  369 
 370 
Added value of this study 371 
Several studies have investigated potential causal nutritional factors in psychiatry using MR. This 372 
study summarizes the current evidence and explores the opportunities and challenges in using this 373 
method to underpin intervention development. This paper also summarises some of the novel 374 
methods in MR, and how they might overcome issues with correlated nutritional exposures, non-375 
linear effects, and to identify potential harms of supplementation. 376 
 377 
Implications of all the available evidence 378 
Several MR studies have shown evidence for causal nutritional factors in psychiatry . A 379 
comprehensive approach to investigating nutritional exposures psychiatry would be beneficial for 380 
the current evidence base and would help to inform intervention development in a resource-381 
constrained field. It is important to consider the validity of findings irrespective of the direction or 382 
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strength of evidence, and to replicate results as new samples, methods and biological insights 383 
become available. 384 
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Table 1: Glossary of MR Terms and potential uses in nutritional psychiatry 20 For more information 422 
about other terms and the  423 
Term Explanation 
F-Statistic The F-statistic measures the strength of genetic instruments. F<10 is 
suggestive of weak instrument bias. 
Multivariable MR Multivariable MR is a technique to account for pleiotropy due to multiple 
correlated exposures. 
MR-PheWAS  
(MR Phenome 
Wide Association 
Study) 
 MR PheWAS is a method using a hypothesis-free approach to scan many 
outcomes for a given exposure using MR methodology. Such approaches 
could be used to test for and identify any potential adverse off-target 
effects of dietary supplementation, providing genetic instruments exist. 
Pleiotropy Horizontal Pleiotropy is where the SNP or SNPs related to the exposure 
are associated with the outcome through a pathway independent of the 
exposure (i.e. a violation of assumption c in figure 1b). 
Pleiotropy can be demonstrated by several methods, including Cochran’s 
Q statistic testing heterogeneity in causal estimates from each SNP, MR-
Egger intercept, and leave-one-out analysis to identify influential outliers 
Population 
Stratification 
Spurious associations may arise in MR where the genetic variant and the 
outcome are associated with ancestral background in a mixed or 
stratified sample. Using genetic associations from within homogenous 
populations, or checking that the GWAS has controlled for population 
substructure in the analysis is important. 
One-sample MR Conventional one-sample MR uses a single sample in which exposure, 
outcome and genetic instrument are measured within the same 
population. One-sample MR may have power issues due to inadequate 
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sample sizes of studies that are required to have genotype, exposure and 
outcome data. 
Two-Sample MR The estimates of the SNP-exposure and SNP-outcome associations used 
in MR analyses are identified in independent studies (usually genome-
wide association studies) 
Two-Step/ 
Mediation MR 
Two-step MR can be used to identify mediating mechanisms between an 
exposure and outcome using two steps- the first to assess the causal 
effect of the exposure on the potential mediator, and the second to 
assess the causal effect of the mediator on the outcome 
424 
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Table 2: Studies using Mendelian randomization in nutritional psychiatry 
Table summarizes current MR studies in nutritional psychiatry. Discrepancies exist between disorders, and the applicability of existing instruments to other 
outcomes, or to a combined ‘cross disorder’ cohort may be fruitful. Results are given as odds ratios per standard deviation change in the exposure unless 
otherwise specified. Abbreviations: IGAP (International Genomics of Alzheimer’s), Psychiatric Genomics Consortium (PGC). For further details of instrument rsids, 
genes and beta coefficients please refer to the original publication.
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1 IGAP International Genomics of Alzheimer’s Project 
2 PGC Psychiatric Genomics Consortium  
 
 
Exposure Study Measure Sample  N MR Method SNPs Results Reported  
OR / beta/ Hazard ratio/ Risk difference 
(95% confidence intervals) p-value 
         
         
V
IT
A
M
IN
S
 
Vitamin D 
 
Maddock 2017 29 Global Cognitive tests  Cross cohort  172,349 Two-sample  2 β 0.00 points per 25(OH)D decreasing 
allele (0.01, 0.01) p>0.99 
Memory tests  β 0.00  points per 25(OH)D decreasing 
allele  (-0.01, 0.01) p=0.6 
Jorde 2015 28 Cognitive Tests  Tromso Study 5,980 One-sample  4 No overall association 
Mokry 2016 25 Alzheimer’s Diagnosis IGAP1 54,162 Two-sample  4 OR 0.8 per SD (0.97, 0.66) p=0.021  
Olsson 2017 27 Dementia Diagnosis Uppsala 
Longitudinal 
Study 
1,087 One-sample 2 HR 1.04 points per effect allele  (0.91, 
1.19)  
Cognitive Impairment 
(MMSE) 
408 One-sample 2 OR 1.03 per effect allele (0.80, 1.34) 
Larsson 2018 26 Alzheimer’s Diagnosis IGAP 54,162 Two-sample  7 OR 0.86 per SD (0.78, 0.94) p = 0.002 
Taylor 2016 48 Schizophrenia Diagnosis PGC2 79,845 Two-sample  4 OR 0.99 per 10% increase (0.97, 1.0) 
Michaelsson 2018 52 Major Depression Diagnosis PGC 173,005 Two-sample  6 OR 1.02 per SD (0.97, 1.08) p = 0·44 
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3 SLCR90_r diagnosis depression… 
        
Vitamin E Liu 2018 41 Alzheimer’s Diagnosis IGAP 54,162 Two-sample  3 OR 0·96 per SD (0·47,1·94) p =0·936 
        
Vitamin B6 Tomioka 2018 43 Schizophrenia Diagnosis Tokushima 
University 
Hospital 
10,689 One-sample 1  OR 0·99 per SD log(B6)  (0·65, 1·51) p= 
0·96 
        
Folate  Larsson 2017 32 Alzheimer’s Diagnosis IGAP 54,162 Two-sample 2 OR 0·98 per SD (0·72, 1·33) p=0·89 
Mollehave 2017 50 Depression (SLCR90_r3) Health 2006 & 
Inter 99  
4,126 One-sample  2  OR 1·18 per effect allele (0·18, 7·66), 
P=0·86 
        
Homocysteine Hu 2016 33 Alzheimer’s Diagnosis 34 studies 9,397 Two-Sample  1   OR 3·37 per SD ( 1·90, 5·95) p = 2·9×10-5 
Larsson 2017 32 Alzheimer’s Diagnosis IGAP 54,162 Two-sample 18 OR 0·99 per SD (0·88, 1·11) 0·86 
Roostaei 2018 67 Alzheimer’s Diagnosis IGAP 54,162 Two-sample  13  OR 1·01 per SD (0·89, 1·15), p=0·84 
Numata 2015 44 Schizophrenia Diagnosis 36 Studies 25,599 Two-sample  1 OR 2·15 per SD (1·39, 3·32) p=5·3x10−4 
Kinoshita 201545 Schizophrenia Diagnosis Meta-analysis 10,378 One-sample 1 OR 1.14 per SD (1.03-1.27), p=1.6x10-2 
Wu 201735 Vascular Dementia 
Diagnosis 
Meta-analysis  1,880 Two-sample  1 OR 4·29 per SD log (hcy) (1·11,16·57) P = 
0·03 
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4 SLCR90_r diagnosis depression… 
B12 Mollehave 2017 50 Depression (SLCR90_r4) Health 2006 & 
Inter 99  
4,126 One-sample  12  0·96 (0·52,1·79), P=0·91 
Larsson 2018 32 Alzheimer’s Diagnosis IGAP 54,162 Two-sample 7 OR 1·11 per SD (0·95, 1·30) p=0·18 
         
M
IN
E
R
A
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Calcium Cheng 201942 Alzheimer’s Diagnosis IGAP 54,162 Two- 
sample  
6 OR 0·74 per SD (0·45, 1·22) p=0·23 
Major Depression Diagnosis PGC  10,640 Two- 
sample  
6 OR 0·92 per SD (0·67, 1·28) p=0·63 
Bipolar Disorder Diagnosis PGC 41,653 Two- 
sample  
7 OR 1·85 per SD (0·74, 4·65) p=0·19 
Schizophrenia Diagnosis PGC 65,967 Two- 
sample 
7 OR 1·85 per SD (0·74, 4·65) p=0·19 
        
Copper Cheng 201942 Alzheimer’s Diagnosis IGAP 54,162 Two- 
sample  
2 OR 0·87 per SD (0·75, 1·00) p=0·05 
Bipolar Disorder Diagnosis PGC 41,653 Two- 
sample  
2 OR 0·87 per SD (0·79, 0·97) p=0·01 
Schizophrenia Diagnosis PGC 65,967 Two- 
sample 
2 OR 0·96 per SD (0·85, 1·08) p=0·47 
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Magnesium Cheng 201942 Alzheimer’s Diagnosis IGAP 54,162 Two- 
sample  
4 OR 0·43 per SD (0·08-2·44) p=0·34 
Major Depression Diagnosis PGC  10,640 Two- 
sample  
3 OR 1·19 per SD (0·22, 6·61) p=0·84 
Bipolar Disorder Diagnosis PGC 41,653 Two- 
sample  
4 OR 8·78 per SD (1·16, 66·26) p=0·04 
Schizophrenia Diagnosis PGC 65,967 Two- 
sample 
4 OR 0·87 per SD (0·24, 3·19) p=0·83 
        
Iron Cheng 201942 Alzheimer’s Diagnosis IGAP 54,162 Two- 
sample  
11 OR 1·02 per SD (0·94, 1·14) p=0·48 
Major Depression Diagnosis PGC   10,640 Two- 
sample  
9 OR 0·98 per SD (0·91, 1·05) p=0·60 
Bipolar Disorder Diagnosis PGC 41,653 Two- 
sample  
11 OR 1·17 per SD (0·89, 1·29) p=0·45 
Schizophrenia Diagnosis PGC 65,967 Two- 
sample 
10 OR 1·04 per SD (0·92, 1·18) p=0·55 
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Zinc Cheng 201942 Alzheimer’s Diagnosis IGAP 54,162 Two- 
sample  
 2 OR 0·99 per SD (0·85, 1·14) p=0·85 
Major Depression Diagnosis PGC 10,640 Two- 
sample  
2 OR 0·99 per SD (0·95, 1·03) p=0·66 
Bipolar Disorder Diagnosis PGC 41,653 Two- 
sample  
2 OR 1·02 per SD (0·91, 1·14) p=0·70 
Schizophrenia Diagnosis PGC 65,967 Two- 
sample 
2 OR 0·94 per SD (0·86, 1·02) p=0·11 
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Isoleucine Larsson 2017 36 Alzheimer’s Diagnosis IGAP 54,162 Two-sample  
  
4  OR 1·35 per SD (1·08,1·69) p=0·007 
Leucine 1  OR 1·16 per SD (95% CI, 0·78–1·72) 
p=0·46 
Valine 1 OR 1·13 per SD (95% CI, 0·82–1·57 
p=0·46 
        
Fasting Glucose Weslowska 2017 53 Depression (BDI) Young Finns 
Study  
1,217 One-Sample  35 -0·43 (-0·79, -0·07) p=0·02 
Li 2018 46 Schizophrenia Diagnosis PGC  77,096 Two-sample  30 OR 0·84 per SD, (0·71,0·99) p=0·038 
BIO-X 26,026 14 OR 1·04 per SD (0·84,1·27) p=0·737 
Ostegaard 201540 Alzheimer’s Diagnosis IGAP 54,162 Two-sample  36 OR 1·12 per SD (0·97, 1·30) p=0·112 
 30 
 
        
Fasting insulin and 
insulin sensitivity 
Ostegaard 201540 Alzheimer’s Diagnosis IGAP 54,162 Two-sample  10 OR 1·32 per SD (0·88, 1·98) p=0.18  
Walter 2016 68 Alzheimer’s Diagnosis IGAP 54,162 Two-sample 9 OR 1·17 per unit (1·02,1·34) p=0.02 
Li 2018 46 Schizophrenia Diagnosis PGC  77,096 Two-sample  13 OR 2·33 per SD (1·40, 3·90) p=0.001 
        
DHA (Omega 3)  Sallis 2014 51 Perinatal  Depression 
(EPDS) 
ALSPAC mothers 2,378 One-sample 4  RD 0·08 (-0·05, 0·22) p=0·21 
        
Plasma APOE Rasmussen37 Alzheimer’s Diagnosis Copenhagen 
General 
Population Study 
and Copenhagen 
City Heart Study 
106,562 One-sample 5 OR 1.41 per mg/dL (1.27, 1.57)  
All Dementia OR 1.33 per mg/dL (1.25, 1.43) 
        
Cholesterol & 
Triglycerides 
Proitsi 2014 39 
 
 
 
 
 
Alzheimer’s Diagnosis Cross Cohort  10,578 Two-Sample  70  OR 0·95 per unit (0·76,1·21) p=0·69 Total 
Cholesterol 
40 OR 1·10 per unit (0·89,1·37) p=0·36  
Triglycerides 
69 1·01 per unit (0·82,1·24) p=0·96  HDL-c 
55 0·90 per unit (0·65,1·25) p=0·53  LDL-c 
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Ostergaard 201540 Alzheimer’s Diagnosis  IGAP 54,162 Two-sample   73  OR 1·94 per SD (1·79-2·10) p=3·1x10-56 
Total Cholesterol 
 39  OR 0·96 per SD (0·87,1·07) p=0·48 
Triglycerides 
71 OR 0·75 per SD (0·69, 0·82) p=1x10-11 
HDL-c 
57 OR 2·31 per SD (2·12, 2·50) p=3x10-87 
LDL-c 
       
Benn 201738 Alzheimer’s Diagnosis  Copenhagen 
General 
Population Study 
and Copenhagen 
City Heart Study 
111,194 One-sample 380 OR 0·57 per mmolL-1 (0·27, 1·17) LDL-c 
Vascular Dementia  OR 0·81 per mmolL-1  (0·34, 1·89) LDL-c 
All Dementia  OR 0·66  per mmolL-1  (0·34, 1·26) LDL-c 
       
Khandaker 201954 
 
Major Depression UK Biobank 367,703 Two-sample 76 OR 1.02 per SD (0.91–1.14) LDL-c 
86 OR 0.97 per SD (0.91–1.03) HDL-c 
51 OR 1.18 per SD (1.09–1.27) Triglycerides 
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Table 3: A rough guide to sample size requirements for MR studies 
An illustration of minimum sample sizes required for MR studies, taken from the online calculator 
available at http://cnsgenomics.com/shiny/mRnd/ 69 Results shown are for a binary outcome, 
assuming 25% cases in study, 0.8 power and alpha 0.05.  
Variance explained Estimated Effect Size 
(OR) 
Minimum Sample size 
   
1% 1.01 42,069,473 
1.1 439,015 
1.5 20,408 
2 5,756 
   
5% 1.01 8,413,895 
1.1 87,803 
1.5 4,082 
2 1,152 
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Table 4: Limitations of MR 20 
Limitation Description Relevance to 
Nutritional 
Psychiatry 
Potential Solution 
    
Lack of 
Available 
Instruments 
Genetic 
instruments are 
unavailable for 
certain exposures  
Lack of GWAS for 
certain 
nutritional 
exposures· 
Also due to poor 
measurement of 
particular 
nutritional 
exposures (e·g· 
serum versus 
intracellular 
magnesium). 
Choose a proxy exposure for which 
data is available. Continue to review 
instruments as nutritional GWAS are 
published. 
Weak 
instrument Bias 
Genetic variants 
that are weakly 
associated with 
an exposure (e.g. 
F-statistic <10) 
will bias estimates 
towards the 
observational 
estimate in one-
Weak 
instruments for 
nutritional 
exposures often 
result from 
limited sample 
sizes of pre-
existing GWAS, 
as well as having 
Increase sample sizes (e·g· through 
publicly available GWAS datasets and 
consortia). 
Explain more variation in the 
exposure using allele scores. 
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sample MR, and 
to the null in Two-
sample MR 
a small 
proportion of 
variance 
explained by 
genetic variation. 
Low Power May be caused by 
small sample size, 
low variance 
explained in the 
exposure by the 
SNP, confounding 
and type 1 error 
rate. 
Inadequate 
power may result 
in null results and 
hinder important 
further research. 
Increase sample size or instrument 
strength where possible 
Power for one-sample MR can be 
calculated using free web application 
at 
http://cnsgenomics.com/shiny/mRnd/ 
69 
Horizontal 
Pleiotropy 
The association 
between the 
genetic variant 
and the outcome 
of interest goes 
through an 
alternative 
pathway to the 
exposure. 
Violates a core 
assumption of 
MR (figure 1c). 
Understand underlying biological 
function of genetic variants. 
Use variants directly coding for 
exposure of interest where possible. 
Use MR-Egger estimation. 
Linkage 
Disequilibrium 
Non-random 
allocation of 
alleles in close 
Confounding can 
be introduced by 
using an allele 
Omit alleles in close genetic proximity 
to others. 
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proximity during 
meiosis. 
close to another 
allele, which 
affects the 
outcome of 
interest through 
another pathway. 
Utilise genetic alleles on separate 
chromosomes  
Use homogeneous populations where 
LD structures will be similar 
Developmental 
Compensation 
(Canalization) 
Individual 
adaptation to a 
genetic change, 
which reduces the 
phenotypic effect 
of the genetic 
change·  
 MR may produce 
causal estimates 
that are below 
the effect 
achieved by 
modifying the 
exposure. 
The extent of the impact of 
canalization on MR is currently 
unclear.  
Population 
Stratification 
Spurious results 
may result from 
using mixed 
populations in 
which the genetic 
variant and 
outcome are 
associated with a 
particular genetic 
background. 
Possible 
limitation of 
vitamin D in 
schizophrenia. 
Use genetic associations derived from 
within homogenous populations only· 
Use summary results statistics that 
have adequately controlled for 
population substructure through e.g. 
principal components analysis or 
linear mixed models. 
Biological 
Complexity 
MR may give 
misleading results 
Several studies 
have suggested a 
Improved understanding of biological 
pathways. 
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due to overly 
simplistic 
interpretation of 
complex 
biological 
pathways. 
non-linear 
association 
between vitamin 
D and various 
outcomes, but 
standard MR 
techniques are 
not able to 
detect this. 
Likewise, MR is 
unable to 
account for time-
limited exposures 
or sensitive 
periods, such as 
intrauterine 
exposures and 
psychiatric 
outcomes. 
Use of novel methods to account for 
non-linear associations. 
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Appendix 1: Search Strategy 
Papers included in this review were identified using the following search strategy (adapted from the 
Cochrane Mental disorders search strategy at https://cmd·cochrane·org/search-strategies-
identification-studies), executed on 5th May 2019. Modified MeSH terms were used for EMBASE/ 
PsychINFO databases· 
1. EATING DISORDERS/ or ANOREXIA NERVOSA/ or BINGE-EATING DISORDER/ or BULIMIA 
NERVOSA/ or FEMALE ATHLETE TRIAD SYNDROME/ or PICA/ 
2. HYPERPHAGIA/ or BULIMIA/ 
3. SELF-INJURIOUS BEHAVIOR/ or SELF MUTILATION/ or SUICIDE/ or SUICIDAL IDEATION/ or 
SUICIDE, ATTEMPTED/ 
4. MOOD DISORDERS/ or AFFECTIVE DISORDERS, PSYCHOTIC/ or BIPOLAR DISORDER/ or 
CYCLOTHYMIC DISORDER/ or DEPRESSIVE DISORDER/ or DEPRESSION, POSTPARTUM/ or 
DEPRESSIVE DISORDER, MAJOR/ or DEPRESSIVE DISORDER, TREATMENT-RESISTANT/ or 
DYSTHYMIC DISORDER/ or SEASONAL AFFECTIVE DISORDER/ 
5. NEUROTIC DISORDERS/ 
6. DEPRESSION/ 
7. ADJUSTMENT DISORDERS/ 
8. exp ANTIDEPRESSIVE AGENTS/ 
9. ANXIETY DISORDERS/ or AGORAPHOBIA/ or NEUROCIRCULATORY ASTHENIA/ or OBSESSIVE-
COMPULSIVE DISORDER/ or OBSESSIVE HOARDING/ or PANIC DISORDER/ or PHOBIC 
DISORDERS/ or STRESS DISORDERS, TRAUMATIC/ or COMBAT DISORDERS/ or STRESS 
DISORDERS, POST-TRAUMATIC/ or STRESS DISORDERS, TRAUMATIC, ACUTE/ 
10. ANXIETY/ or ANXIETY, CASTRATION/ or KORO/ 
11. ANXIETY, SEPARATION/ 
12. PANIC/ 
13. exp ANTI-ANXIETY AGENTS/ 
14. SOMATOFORM DISORDERS/ or BODY DYSMORPHIC DISORDERS/ or CONVERSION 
DISORDER/ or HYPOCHONDRIASIS/ or NEURASTHENIA/ 
15. HYSTERIA/ 
16. MUNCHAUSEN SYNDROME BY PROXY/ or MUNCHAUSEN SYNDROME/ 
17. FATIGUE SYNDROME, CHRONIC/ 
18. OBSESSIVE BEHAVIOR/ 
19. COMPULSIVE BEHAVIOR/ or BEHAVIOR, ADDICTIVE/ 
20. IMPULSE CONTROL DISORDERS/ or FIRESETTING BEHAVIOR/ or GAMBLING/ or 
TRICHOTILLOMANIA/ 
21. STRESS, PSYCHOLOGICAL/ or BURNOUT, PROFESSIONAL/ 
22. SEXUAL DYSFUNCTIONS, PSYCHOLOGICAL/ or VAGINISMUS/ 
23. ANHEDONIA/ 
24. AFFECTIVE SYMPTOMS/ 
25. *MENTAL DISORDERS/ 
26. (eating disorder* or anorexia nervosa or bulimi* or binge eat* or (self adj (injur* or 
mutilat*)) or suicide* or suicidal or parasuicid* or mood disorder* or affective disorder* or 
bipolar i or bipolar ii or (bipolar and (affective or disorder*)) or mania or manic or 
cyclothymic* or depression or depressive or dysthymi* or neurotic or neurosis or 
adjustment disorder* or antidepress* or anxiety disorder* or agoraphobia or obsess* or 
compulsi* or panic or phobi* or ptsd or posttrauma* or post trauma* or combat or 
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somatoform or somati#ation or medical* unexplained or body dysmorphi* or conversion 
disorder or hypochondria* or neurastheni* or hysteria or munchausen or chronic fatigue* 
or gambling or trichotillomania or vaginismus or anhedoni* or affective symptoms or 
mental disorder* or mental health)·ti· 
27. Schizophrenia/ or schizophrenia·mp·  
28. depression·mp· or Depression/ 
29. major depressive disorder·mp· or Depressive Disorder, Major/  
30. dementia·mp· or Dementia/ or Frontotemporal Dementia/ or Dementia, Vascular/ or 
Dementia, Multi-Infarct/  
31. autism·mp· or Autistic Disorder/  
32. eating disorder·mp· or "Feeding and Eating Disorders"/  
33. Borderline Personality Disorder/ or Mental Disorders/ or borderline personality·mp· or 
Personality Disorders/ 
34. psychosis·mp· or Psychotic Disorders/ 
35. exp "psychiatry and psychology (non mesh)"/ or psychiatry/ 
36. Attention Deficit Disorder with Hyperactivity/ or ADHD.mp./ or "attention deficit and 
disruptive behavior disorders"/ or child behavior disorders/ 
37. neurodevelopmental disorder.mp. or Neurodevelopmental Disorders/  
38. communication disorders/ or language disorders/ or dyslexia/ or language development 
disorders/ or speech disorders/ or learning disorders/ or intellectual disability/ 
39. Developmental Disabilities/ or Motor Skills Disorders/ or motor delay.mp. 
40. 1 OR 2 OR 3 OR 4 OR 5 OR 6 OR 7 OR 8 OR 9 OR 10 OR 11 OR 12 OR 13 OR 14 OR 15 OR 16 
OR 17 OR 18 OR 19 OR 20 OR 21 OR 22 OR 23 OR 24 OR 25 OR 26 OR 27 OR 28 OR 29 OR 30 
OR 31 OR 32 OR 33 OR 34 OR 35 OR 36 OR 37 OR 38 OR 39 
41. mendelian adj2 random* 
42. Mendelian Randomization Analysis/ or mendelian randomization·mp· 
43. instrumental adj2 variable 
44. 41 OR 42OR 43 
45. 40 AND 44 
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Appendix 2: Flow chart for identification and inclusion of studies· (Numbers for inclusion do not 
add up to 26 as some studies investigated multiple outcomes·) 
 
 
 
 
 
 
 
Appendix 3: Excluded papers 
The following papers were identified in the search strategy as potentially relevant. Reasons for 
exclusion from the current review is given where appropriate. 
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1a Mendelian Randomization as a ‘natural’ Randomized Controlled Trial
MR has been compared to a randomized controlled trial, with random allocation of genetic alleles at 
conception could be considered analogous to random allocation of interventions in a trial.
1b Assumptions in Mendelian Randomization
MR assumes that the genetic variants are: a. associated with the exposure of interest; b. not associated with 
confounders; and c. only associated with the outcome through the exposure
Genetic Variant/s Nutritional Exposure Mental Illness
Confounder/s
a
b
c
1c Two-sample Mendelian Randomization
Two-sample MR takes estimates of the SNP-exposure association from one population (e.g. a nutritional 
exposure GWAS) and the SNP-outcome association from a separate sample (e.g. a psychiatric outcome GWAS).
Genetic Variant(s) Nutritional Exposure Mental Illness
Confounder(s)
First Sample is used to estimate the SNP-exposure association (i.e. genetic contribution to nutritional status) 
Second Sample is used to estimate the SNP-outcome association (i.e. genetic contribution of the exposure SNP(s) on the outcome)
Figure 2: A theoretical pipeline for the use of MR studies in intervention development 
Whilst many have compared MR to ‘nature’s RCT’, it may be more realistic to see MR studies as an 
interim step in intervention development. 
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3a Two-step Mendelian Randomization
Two-step MR can be used to identify mediating mechanisms between an exposure and outcome using 
separate MR analyses which are combined in a traditional mediation analysis.
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3b Multivariable Mendelian Randomization
Multivariable MR can be used where genetic variants are related to multiple correlated exposures. For 
example, a SNP for one lipid will often be correlated with others. This technique could be used to untangle 
potentially opposing associations between omega 3 (EPA/ DHA) and omega 6 fatty acids.
